Imux stock forecast 2025 iMUX in 2025 may track biotech

IMUX in 2025 may track biotech innovation indices closely; upward momentum in sector rankings often correlates with improved institutional coverage and brokerage upgrades. Immunic didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With the cash burn rate up 5.8% in the last year, it seems that the company is ratcheting up investment in the business over time. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . $IMUX insiders have traded $IMUX stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales. IMUX stock forecast 2025 is closely tied to biotech sector dynamics, where Nasdaq biotech indices have shown volatility due to macroeconomic pressures. In 2025, a pipeline breakthrough could widen price-to-sales multiples if revenue projections exceed $200M.